NANOBIOTIX (EPA:NANO) | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
NANOBIOTIX

PRESS RELEASE

published on 09/30/2025 at 22:15, 2 months 4 days ago

NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results
Nanobiotix provides business update & reports 2025 half year financial results. Highlights clinical development program & financial performance

Financial Results Financial Performance Business Update Clinical Development NANOBIOTIX
BRIEF

published on 09/30/2025 at 00:35, 2 months 5 days ago

NANOBIOTIX Reports Promising Phase 1 Results for JNJ-1900 (NBTXR3) in R/M-HNSCC

Phase 1 Trial NANOBIOTIX Clinical Study Results R/M-HNSCC JNJ-1900 (NBTXR3)
PRESS RELEASE

published on 09/30/2025 at 00:30, 2 months 5 days ago

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC
Nanobiotix announces updated phase 1 results supporting JNJ-1900 plus anti-PD-1 as a new option in R/M-HNSCC. Promising local and systemic responses presented at ASTRO 2025

NANOBIOTIX Anti-PD-1 JNJ-1900 R/M-HNSCC ASTRO 2025
BRIEF

published on 09/17/2025 at 22:20, 2 months 17 days ago

New Positive Results for NANOBIOTIX in Phase 1 Melanoma Study

Efficiency Melanoma NANOBIOTIX Phase 1 JNJ-1900
PRESS RELEASE

published on 09/17/2025 at 22:15, 2 months 17 days ago

NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1
Nanobiotix announces new results from a Phase 1 study evaluating JNJ-1900 (NBTXR3) in combination with immune checkpoint inhibitors as a 2L+ therapy for patients with primary cutaneous melanoma resistant to anti-PD-1. Favorable safety profile and early efficacy signals observed

Melanoma NANOBIOTIX Immune Checkpoint Inhibitors Phase 1 Study JNJ-1900
BRIEF

published on 09/12/2025 at 19:05, 2 months 22 days ago

Nanobiotix Announces Voting Rights and Share Capital Details

Voting Rights Shares Euronext Nasdaq NANOBIOTIX
PRESS RELEASE

published on 09/12/2025 at 19:00, 2 months 22 days ago

Voting Rights and Shares Capital of the Company
Nanobiotix releases voting rights and shares capital details. The company is listed on Euronext Paris and Nasdaq, pioneering biotechnology for treatment advancements

Euronext Paris Voting Rights Nasdaq Shares Capital NANOBIOTIX
BRIEF

published on 09/02/2025 at 22:20, 3 months 2 days ago

Nanobiotix at the HC Wainwright Global Investment Conference

Investors Biotechnology Conference Therapeutics NANOBIOTIX
PRESS RELEASE

published on 09/02/2025 at 22:15, 3 months 2 days ago

Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Nanobiotix to participate in H.C. Wainwright 27th Annual Global Investment Conference with a fireside chat featuring company management. Nanoparticle-based treatments for cancer and major diseases

Fireside Chat NANOBIOTIX H.C. Wainwright Conference Late-stage Biotechnology Nanoparticle-based Treatments
BRIEF

published on 08/27/2025 at 08:05, 3 months 8 days ago

Nanobiotix Announces Voting Rights and Shares Capital Update

Euronext Paris Voting Rights Biotechnology Shares Capital NANOBIOTIX

Accesswire

Published on 12/05/2025 at 02:35, 3 hours 32 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 3 hours 37 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 5 hours 7 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 2 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 7 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 2 hours 37 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 16 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 42 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 52 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 57 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 12 hours 7 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 22 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 23 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 6 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE